Ribon Therapeutics
OverviewSuggest Edit
Ribon Therapeutics is pioneering the discovery and development of monoPARP (mono ADP-ribose polymerase) inhibitors to block cancer cells’ fundamental ability to survive under stress
| Type | Private | |
| Founded | 2015 | |
| HQ | Cambridge, MA, US | Map |
| Website | ribontx.com |
Recent NewsAll News
Latest Updates
| Employees (est.) (Jan 2022) | 52 | (-1%) |
| Cybersecurity rating | B | More |
Key People/Management at Ribon Therapeutics
Victoria Richon
President and Chief Executive Officer, Director
James Audia
Executive Director, Chicago Biomedical Consortium
Ribon Therapeutics
Executive Director, Chicago Biomedical Consortium
Jodie Morrison
Chair of The Board Of Directors
Laura Brass
Managing Director, Novartis Venture Fund
Heike Keilhack
Chief Scientific Officer
Ribon Therapeutics Office Locations
Ribon Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
35 Cambridgepark Dr
Ribon Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Ribon Therapeutics total Funding | $65 m |
Ribon Therapeutics latest funding size | $65 m |
Time since last funding | 6 months ago |
Ribon Therapeutics investors | U.S. Venture Partners (USVP), Osage University Partners, Takeda Ventures, Novartis Venture Fund, The Column Group, Peregrine Ventures, GV, Johnson & Johnson Innovation, Deerfield Management, Euclidean Capital, U.S. Venture Partners, AbbVie Ventures, Bristol Myers Squibb, Monashee Investment Management, Avego Bioscience Capital |
Ribon Therapeutics's latest funding round in July 2021 was reported to be $65 m. In total, Ribon Therapeutics has raised $65 m
Ribon Therapeutics Cybersecurity Score
Ribon Therapeutics Online and Social Media Presence
Ribon Therapeutics's Trends
Ribon Therapeutics Blogs
September 27, 2021
Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech
Cambridge, MA – September 27, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced it has been …
The post Ribon Therapeutics Named a “Fierce 15” Biotech Company by Fierce Biotech appeared first on Ribon Therapeut…
September 01, 2021
Ribon Therapeutics Announces Key Management Promotions
Heike Keilhack, Ph.D., Promoted to Chief Scientific Officer Kevin Kuntz, Ph.D., Promoted to Chief Drug Development Officer Cambridge, MA – September 1, 2021 – Ribon …
The post Ribon Therapeutics Announces Key Management Promotions appeared first on Ribon Therapeutics.
July 22, 2021
Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397
Small molecule inhibitor of PARP7 restores Type I interferon signaling in tumor cells Data validate therapeutic strategy of targeting PARP7, a key vulnerability in cancer …
The post Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397 appe…
July 14, 2021
Ribon Therapeutics Secures $65 Million Financing
Proceeds Support Advancement of Lead Product Candidates RBN-2397 and RBN-3143 Through Key Clinical Milestones Cambridge, MA – July 14, 2021 – Ribon Therapeutics, a clinical …
The post Ribon Therapeutics Secures $65 Million Financing appeared first on Ribon Therapeutics.
June 28, 2021
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer
Cambridge, MA – June 28, 2021 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of …
The post Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer appeared first on Ribon Therapeuti…
June 04, 2021
Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting
RBN-2397 was well tolerated and demonstrated evidence of target inhibition and preliminary signs of clinical activity One partial response (PR) and nine patients with stable …
The post Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients …
Ribon Therapeutics Frequently Asked Questions
When was Ribon Therapeutics founded?
Ribon Therapeutics was founded in 2015.
Who are Ribon Therapeutics key executives?
Ribon Therapeutics's key executives are Victoria Richon, James Audia and Ribon Therapeutics.
How many employees does Ribon Therapeutics have?
Ribon Therapeutics has 52 employees.
Who are Ribon Therapeutics competitors?
Competitors of Ribon Therapeutics include Venn Therapeutics, Zenith Epigenetics and Entrinsic Bioscience.
Where is Ribon Therapeutics headquarters?
Ribon Therapeutics headquarters is located at 35 Cambridgepark Dr, Cambridge.
Where are Ribon Therapeutics offices?
Ribon Therapeutics has an office in Cambridge.
How many offices does Ribon Therapeutics have?
Ribon Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies